Tags

Type your tag names separated by a space and hit enter

Reduction in glycated albumin can predict change in HbA1c: comparison of oral hypoglycaemic agent and insulin treatments.
Diabet Med. 2012 Jan; 29(1):74-9.DM

Abstract

AIM

To investigate whether the change in glycated albumin 3 weeks after initiating anti-diabetes treatment (oral hypoglycaemic agent or insulin) could predict the corresponding change in HbA(1c) 3 months later in Korean patients with Type 2 diabetes.

METHODS

A total of 140 patients were enrolled into two groups: group I (insulin-based; n = 100) and group II (oral hypoglycaemic agent-based; n = 40). Both glycated albumin and HbA(1c) levels were measured as 'glucose control markers' during hospitalization. Glycated albumin was measured again at 3 weeks (first visit) after the initial measurement, and HbA(1c) was measured at 3 months (second visit) after the initial measurement.. The change in glucose control marker was defined as 100 × (follow-up glucose control marker--hospital glucose control marker)/hospital glucose control marker.

RESULTS

In both groups, the change in glycated albumin at the first visit and in HbA(1c) at the second visit showed a moderate linear relationship (r = 0.735; P < 0.01). In group II (r = 0.778; P < 0.01), a slightly stronger linear relationship was demonstrated than in group I (r = 0.738; P < 0.001); however, there was no statistically significant difference between the two groups. A correlation coefficient between the change in glycated albumin and HbA(1c) was not affected by sex, age, BMI, haemoglobin, serum creatinine or albumin.

CONCLUSION

The reduction in glycated albumin 3 weeks after the initiation of treatment corresponded with the reduction in HbA(1c) 3 months after starting treatment in both the group treated with a oral hypoglycaemic agent and the insulin-treated group of Korean patients with Type 2 diabetes.

Authors+Show Affiliations

Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21781151

Citation

Won, H K., et al. "Reduction in Glycated Albumin Can Predict Change in HbA1c: Comparison of Oral Hypoglycaemic Agent and Insulin Treatments." Diabetic Medicine : a Journal of the British Diabetic Association, vol. 29, no. 1, 2012, pp. 74-9.
Won HK, Kim KJ, Lee BW, et al. Reduction in glycated albumin can predict change in HbA1c: comparison of oral hypoglycaemic agent and insulin treatments. Diabet Med. 2012;29(1):74-9.
Won, H. K., Kim, K. J., Lee, B. W., Kang, E. S., Cha, B. S., & Lee, H. C. (2012). Reduction in glycated albumin can predict change in HbA1c: comparison of oral hypoglycaemic agent and insulin treatments. Diabetic Medicine : a Journal of the British Diabetic Association, 29(1), 74-9. https://doi.org/10.1111/j.1464-5491.2011.03386.x
Won HK, et al. Reduction in Glycated Albumin Can Predict Change in HbA1c: Comparison of Oral Hypoglycaemic Agent and Insulin Treatments. Diabet Med. 2012;29(1):74-9. PubMed PMID: 21781151.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduction in glycated albumin can predict change in HbA1c: comparison of oral hypoglycaemic agent and insulin treatments. AU - Won,H K, AU - Kim,K J, AU - Lee,B-W, AU - Kang,E S, AU - Cha,B S, AU - Lee,H C, PY - 2011/7/26/entrez PY - 2011/7/26/pubmed PY - 2012/2/15/medline SP - 74 EP - 9 JF - Diabetic medicine : a journal of the British Diabetic Association JO - Diabet Med VL - 29 IS - 1 N2 - AIM: To investigate whether the change in glycated albumin 3 weeks after initiating anti-diabetes treatment (oral hypoglycaemic agent or insulin) could predict the corresponding change in HbA(1c) 3 months later in Korean patients with Type 2 diabetes. METHODS: A total of 140 patients were enrolled into two groups: group I (insulin-based; n = 100) and group II (oral hypoglycaemic agent-based; n = 40). Both glycated albumin and HbA(1c) levels were measured as 'glucose control markers' during hospitalization. Glycated albumin was measured again at 3 weeks (first visit) after the initial measurement, and HbA(1c) was measured at 3 months (second visit) after the initial measurement.. The change in glucose control marker was defined as 100 × (follow-up glucose control marker--hospital glucose control marker)/hospital glucose control marker. RESULTS: In both groups, the change in glycated albumin at the first visit and in HbA(1c) at the second visit showed a moderate linear relationship (r = 0.735; P < 0.01). In group II (r = 0.778; P < 0.01), a slightly stronger linear relationship was demonstrated than in group I (r = 0.738; P < 0.001); however, there was no statistically significant difference between the two groups. A correlation coefficient between the change in glycated albumin and HbA(1c) was not affected by sex, age, BMI, haemoglobin, serum creatinine or albumin. CONCLUSION: The reduction in glycated albumin 3 weeks after the initiation of treatment corresponded with the reduction in HbA(1c) 3 months after starting treatment in both the group treated with a oral hypoglycaemic agent and the insulin-treated group of Korean patients with Type 2 diabetes. SN - 1464-5491 UR - https://www.unboundmedicine.com/medline/citation/21781151/Reduction_in_glycated_albumin_can_predict_change_in_HbA1c:_comparison_of_oral_hypoglycaemic_agent_and_insulin_treatments_ L2 - https://doi.org/10.1111/j.1464-5491.2011.03386.x DB - PRIME DP - Unbound Medicine ER -